The Arg972 Variant in Insulin Receptor Substrate-1 Is Associated With an Increased Risk of Secondary Failure to Sulfonylurea in Patients With Type 2 Diabetes
Copyright policy )The Arg972 Variant in Insulin Receptor Substrate-1 Is Associated With an Increased Risk of Secondary Failure to Sulfonylurea in Patients With Type 2 Diabetes
OBJECTIVE—The aim of this study was to investigate whether diabetic patients carrying the Arg972 insulin receptor substrate-1 (IRS-1) variant are at increased risk for secondary failure to sulfonylurea. RESEARCH DESIGN AND METHODS—A total of 477 unrelated Caucasian type 2 diabetic patients were recruited according to the following criteria: onset of diabetes after age 35 years, absence of ketonuria at diagnosis, and anti-GAD− antibody. Type 2 diabetes was diagnosed according to the American Diabetes Association criteria. Patients with secondary sulfonylurea failure were defined as those requiring insulin due to uncontrolled hyperglycemia (fasting plasma glucose >300 mg/dl) despite sulfonylurea-metformin combined therapy, appropriate diet, and absence of any conditions causing hyperglycemia. RESULTS—Of the total patients, 53 (11.1%) were heterozygous for the Arg972 IRS-1 variant, 1 (0.2%) was homozygous, and the remainder (88.7%) were homozygous for the wild-type allele. The genotype frequency of the Arg972 IRS-1 variant was 8.7% among diabetic patients well controlled with oral therapy and 16.7% among patients with secondary failure to sulfonylurea (odds ratio 2.1 [95% CI 1.18–3.70], P = 0.01). Adjustment for age, sex, BMI, metabolic control, age at diagnosis, duration of diabetes, and Pro12Ala polymorphism of peroxisome proliferator–activated receptor-γ2 gene in a logistic regression analysis with secondary failure to sulfonylurea as a dependent variable did not change this association (2.0 [1.38–3.86], P = 0.038). CONCLUSIONS—These data demonstrate that the Arg972 IRS-1 variant is associated with increased risk for secondary failure to sulfonylurea, thus representing a potential example of pharmacogenetics in type 2 diabetes.
Male, age distribution, arginine, insulin receptor substrate-1 protein, genetic variability, middle aged, genetic polymorphism, Treatment Failure, proline, alanine; arginine; glutamate decarboxylase antibody; insulin; insulin receptor substrate 1; metformin; oral antidiabetic agent; peroxisome proliferator activated receptor gamma; peroxisome proliferator activated receptor gamma 2; proline; sulfonylurea derivative; unclassified drug; antidiabetic agent; insulin receptor substrate 1 protein; insulin receptor substrate-1 protein; phosphoprotein; adult; age distribution; aged; article; body mass; Caucasian; disease duration; female; genetic polymorphism; heterozygosity; homozygosity; hormone receptor interaction; human; hyperglycemia; insulin treatment; ketonuria; logistic regression analysis; major clinical study; male; metabolic regulation; non insulin dependent diabetes mellitus; onset age; pharmacogenetics; protein variant; risk assessment; treatment failure; amino acid substitution; genetic marker; genetic variability; genetics; middle aged; Adult; Aged; Amino Acid Substitution; Arginine; Diabetes Mellitus, Type 2; European Continental Ancestry Group; Female; Genetic Markers; Humans; Hypoglycemic Agents; Male; Middle Aged; Phosphoproteins; Sulfonylurea Compounds; Treatment Failure; Variation (Genetics), ketonuria, adult, insulin receptor substrate 1 protein, article, peroxisome proliferator activated receptor gamma, risk assessment, Middle Aged, phosphoprotein, unclassified drug, aged, female, pharmacogenetic, Female, protein variant, genetic marker, alanine, amino acid substitution, onset age, Adult, Genetic Markers, glutamate decarboxylase antibody, insulin, non insulin dependent diabetes mellitu, oral antidiabetic agent, peroxisome proliferator activated receptor gamma 2, Caucasian, Arginine, White People, male, 616, heterozygosity, Humans, Hypoglycemic Agents, human, insulin treatment, treatment failure, Aged, insulin receptor substrate 1, Genetic Variation, antidiabetic agent, Phosphoproteins, major clinical study, Sulfonylurea Compounds, Amino Acid Substitution, Diabetes Mellitus, Type 2, sulfonylurea derivative, logistic regression analysi, Insulin Receptor Substrate Proteins, hyperglycemia, metabolic regulation, disease duration, homozygosity, genetic, metformin, hormone receptor interaction, body ma
Male, age distribution, arginine, insulin receptor substrate-1 protein, genetic variability, middle aged, genetic polymorphism, Treatment Failure, proline, alanine; arginine; glutamate decarboxylase antibody; insulin; insulin receptor substrate 1; metformin; oral antidiabetic agent; peroxisome proliferator activated receptor gamma; peroxisome proliferator activated receptor gamma 2; proline; sulfonylurea derivative; unclassified drug; antidiabetic agent; insulin receptor substrate 1 protein; insulin receptor substrate-1 protein; phosphoprotein; adult; age distribution; aged; article; body mass; Caucasian; disease duration; female; genetic polymorphism; heterozygosity; homozygosity; hormone receptor interaction; human; hyperglycemia; insulin treatment; ketonuria; logistic regression analysis; major clinical study; male; metabolic regulation; non insulin dependent diabetes mellitus; onset age; pharmacogenetics; protein variant; risk assessment; treatment failure; amino acid substitution; genetic marker; genetic variability; genetics; middle aged; Adult; Aged; Amino Acid Substitution; Arginine; Diabetes Mellitus, Type 2; European Continental Ancestry Group; Female; Genetic Markers; Humans; Hypoglycemic Agents; Male; Middle Aged; Phosphoproteins; Sulfonylurea Compounds; Treatment Failure; Variation (Genetics), ketonuria, adult, insulin receptor substrate 1 protein, article, peroxisome proliferator activated receptor gamma, risk assessment, Middle Aged, phosphoprotein, unclassified drug, aged, female, pharmacogenetic, Female, protein variant, genetic marker, alanine, amino acid substitution, onset age, Adult, Genetic Markers, glutamate decarboxylase antibody, insulin, non insulin dependent diabetes mellitu, oral antidiabetic agent, peroxisome proliferator activated receptor gamma 2, Caucasian, Arginine, White People, male, 616, heterozygosity, Humans, Hypoglycemic Agents, human, insulin treatment, treatment failure, Aged, insulin receptor substrate 1, Genetic Variation, antidiabetic agent, Phosphoproteins, major clinical study, Sulfonylurea Compounds, Amino Acid Substitution, Diabetes Mellitus, Type 2, sulfonylurea derivative, logistic regression analysi, Insulin Receptor Substrate Proteins, hyperglycemia, metabolic regulation, disease duration, homozygosity, genetic, metformin, hormone receptor interaction, body ma
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).67 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!